Genmab (CPSE:GMAB) - Aandelenkoers, Nieuws & Analyse

GMAB Overzicht aandelen

Genmab A/S ontwikkelt therapeutica op basis van antilichamen voor de behandeling van kanker en andere ziekten, voornamelijk in Denemarken. Meer informatie

GMAB fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	4/6
Prestaties in het verleden	4/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 84.5% onder onze schatting van de reële waarde

De winst zal naar verwachting met 23.73% per jaar groeien

De winst groeide het afgelopen jaar met 12.9%

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Geen risico's gedetecteerd voor GMAB uit onze risicocontroles.

Genmab A/S Concurrenten

Bavarian Nordic

CPSE:BAVA

DKK 13.3b

H. Lundbeck

CPSE:HLUN B

DKK 42.7b

ALK-Abelló

CPSE:ALK B

DKK 34.9b

Neurocrine Biosciences

NasdaqGS:NBIX

US$11.9b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Genmab
Historische aandelenkoersen
Huidige aandelenkoers	DKK 1,463.50
52 Week Hoogtepunt	DKK 2,283.00
52 Week Laag	DKK 1,450.00
Bèta	0.86
11 maand verandering	-6.40%
3 maanden verandering	-19.61%
1 Jaar Verandering	-34.08%
33 jaar verandering	-44.59%
5 jaar verandering	-6.52%
Verandering sinds IPO	528.11%

Recent nieuws en updates

The Price Is Right For Genmab A/S (CPH:GMAB)

Sep 19

We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated

Aug 22

Recent updates

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Feb 21

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Nov 13

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Jun 19

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

May 29

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Mar 18

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Feb 27

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Dec 17

Rendement voor aandeelhouders

	GMAB	DK Biotechs	DK Markt
7D	-9.0%	-11.8%	-3.1%
1Y	-34.1%	-10.0%	5.7%

Rendement versus industrie: GMAB presteerde slechter dan de Danish Biotechs -sector, die het afgelopen jaar een rendement van -10 % opleverde.

Rendement versus markt: GMAB presteerde slechter dan Danish Market, dat het afgelopen jaar een rendement van 5.7 % opleverde.

Prijsvolatiliteit

Is GMAB's price volatile compared to industry and market?
GMAB volatility
GMAB Average Weekly Movement	3.3%
Biotechs Industry Average Movement	7.8%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.5%
10% least volatile stocks in DK Market	2.4%

Stabiele aandelenkoers: GMAB heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van GMAB is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1999	2,635	Jan G.J. de Winkel	www.genmab.com

Genmab A/S ontwikkelt therapeutica op basis van antilichamen voor de behandeling van kanker en andere ziekten, voornamelijk in Denemarken. Het bedrijf brengt DARZALEX op de markt, een humaan monoklonaal antilichaam voor de behandeling van patiënten met multipel myeloom (MM); teprotumumab voor de behandeling van schildklieroogaandoeningen; en amivantamab voor gevorderde of gemetastaseerde maag- of slokdarmkanker en NSCLC. Haar producten omvatten daratumumab voor de behandeling van MM, niet-MM bloedkankers en AL amyloïdose; GEN1047; tisotumab vedotin voor de behandeling van baarmoederhals-, eierstok- en solide kankers; DuoBody-PD-L1x4-1BB, en DuoBody-CD40x4-1BB voor de behandeling van solide tumoren; Epcoritamab voor recidief/refractair diffuus groot B-cel lymfoom en chronische lymfocytaire leukemie; en HexaBody-CD38 en GEN3017 voor de behandeling van hematologische maligniteiten.

Genmab A/S Samenvatting

Hoe verhouden de winst en inkomsten van Genmab zich tot de beurswaarde?
GMAB fundamentele statistieken
Marktkapitalisatie	DKK 92.09b
Inkomsten(TTM)	DKK 4.70b
Inkomsten(TTM)	DKK 19.84b

19.8x

Koers/Winstverhouding

4.7x

P/S-verhouding

Is GMAB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GMAB resultatenrekening (TTM)
Inkomsten	DKK 19.84b
Kosten van inkomsten	DKK 774.00m
Brutowinst	DKK 19.07b
Overige uitgaven	DKK 14.37b
Inkomsten	DKK 4.70b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	74.03
Brutomarge	96.10%
Nettowinstmarge	23.69%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde GMAB op de lange termijn?

Bekijk historische prestaties en vergelijking

GMAB Overzicht aandelen

Beloningen

Risicoanalyse

Genmab A/S Concurrenten

CPSE:BAVA

DKK 13.3b

CPSE:HLUN B

DKK 42.7b

CPSE:ALK B

DKK 34.9b

NasdaqGS:NBIX

US$11.9b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

The Price Is Right For Genmab A/S (CPH:GMAB)

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

The Price Is Right For Genmab A/S (CPH:GMAB)

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Consensus EPS estimates fall by 15%

Genmab A/S Takes Full Control of Acasunlimab Development Program

Consensus EPS estimates increase by 14%

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind